Pages

Wednesday, March 27, 2013

Potential Markers for Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Markers such as CA9 and VEGFR1/2 in primary tumors might serve as predictors of a good response to sunitinib in patients with metastatic clear cell renal cell carcinoma, researchers reported at the 28th Annual European Association of Urology Congress. Among 20 patients, elevated vessel staining of VEGFR1/2 and increased microvessel density and CA9 staining in the primary tumor were observed in patients with a response to sunitinib. High CA9 protein expression was associated with longer overall survival.

No comments:

Post a Comment